The effect of dose on the safety and immunogenicity of the VSV Ebola candidate vaccine: a randomised double-blind, placebo-controlled phase 1/2 trial

Csaki Huttner, Angela; Dayer, Julie-Anne; Yerly Ferrillo, Sabine; Combescure, Christophe; Auderset, Floriane; Desmeules, Jules Alexandre; Eickmann, Markus; Finckh, Axel; Goncalves Cabecinhas, Ana Rita; Hooper, Jay W; Kaya, Gurkan; Krähling, Verena; Kwilas, Steve; Lemaitre, Barbara; Matthey, Alain; Silvera, Peter; Becker, Stephan; Fast, Patricia E; Moorthy, Vasee; Kieny, Marie Paule; Kaiser, Laurent; Siegrist, Claire-Anne

Advanced search

Browse by...

Deposit

Highlights

More informations

Title		The effect of dose on the safety and immunogenicity of the VSV Ebola candidate vaccine: a randomised double-blind, placebo-controlled phase 1/2 trial
Authors		Csaki Huttner, Angela Dayer, Julie-Anne Yerly Ferrillo, Sabine Combescure, Christophe Auderset, Floriane Desmeules, Jules Alexandre Eickmann, Markus Finckh, Axel Goncalves Cabecinhas, Ana Rita Hooper, Jay W Kaya, Gurkan Krähling, Verena Kwilas, Steve Lemaitre, Barbara Matthey, Alain Silvera, Peter Becker, Stephan Fast, Patricia E Moorthy, Vasee Kieny, Marie Paule Kaiser, Laurent Siegrist, Claire-Anne show all authors [1 - 22]
Published in		The Lancet Infectious Diseases. 2015, vol. 15, no. 10, p. 1156–1166
Abstract		Safe and effective vaccines against Ebola could prevent or control outbreaks. The safe use of replication-competent vaccines requires a careful dose-selection process. We report the first safety and immunogenicity results in volunteers receiving 3 × 10(5) plaque-forming units (pfu) of the recombinant vesicular stomatitis virus-based candidate vaccine expressing the Zaire Ebola virus glycoprotein (rVSV-ZEBOV; low-dose vaccinees) compared with 59 volunteers who had received 1 ×10(7) pfu (n=35) or 5 × 10(7) pfu (n=16) of rVSV-ZEBOV (high-dose vaccinees) or placebo (n=8) before a safety-driven study hold.
Identifiers		DOI: 10.1016/S1473-3099(15)00154-1 PMID: 26248510
Full text		Article (Published version) (1.8 MB) - Limited access to UNIGE
Structures		Faculté de médecine / Section de médecine fondamentale / Département de pathologie et immunologie Faculté de médecine / Section de médecine clinique / Département de pédiatrie Faculté de médecine / Section de médecine clinique / Département de santé et médecine communautaires
Research groups		Centre de vaccinologie et d'immunologie néonatale (177) Groupe Desmeules Jules (pharmacologie/toxicologie) (567) Groupe Laurent Kaiser (virologie clinique) (668) Rôle du CD44 (809) Mécanisme de l'inflammation articulaire (44) Epidémiologie clinique (115)
Citation (ISO format)		CSAKI HUTTNER, Angela et al. The effect of dose on the safety and immunogenicity of the VSV Ebola candidate vaccine: a randomised double-blind, placebo-controlled phase 1/2 trial. In: The Lancet Infectious Diseases, 2015, vol. 15, n° 10, p. 1156–1166. https://archive-ouverte.unige.ch/unige:76362